MCS in Treating Lower Urinary Tract Symptoms (LUTS) Suggestive of Benign Prostatic Hyperplasia

• Status: Terminated
• Trial end date: 2009-10-01

Summary

Phase III, Randomized, double-blind, parallel placebo-controlled study. Two arms: MCS (30mg/day) vs. placebo.

Subproject MCS-2: alpha-blocker naïve subjects

Subproject MCS-3: subjects responding poorly to alpha-blocker

• Phase: Phase 3

Details

• Lead Sponsor: Health Ever Bio-Tech Co., Ltd.